Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III VANISH-306 study of oral ibrexafungerp in VVC meets primary endpoint

April 21, 2020

Cara reports topline data from KALM-2 trial of Korsuva in hemodialysis patients with pruritus

April 21, 2020

IMDC recommends continuation of phase III trial of eryaspase in advanced pancreatic cancer

April 21, 2020

Nucorion begins first-in-human study of NCO-48 fumarate for hepatitis B

April 21, 2020

New nitric oxide production inhibitors presented by FronThera US Pharmaceuticals

April 21, 2020

Cardurion Pharmaceuticals synthesizes new CAMK2 inhibitors

April 21, 2020

Genzyme identifies new GALC inhibitors

April 21, 2020

Regenacy Pharmaceuticals discloses HDAC1 and/or HDAC2 inhibitors

April 21, 2020

Arbidol shows superior efficacy compared to lopinavir/ritonavir in treating COVID-19

April 21, 2020

RAPT Therapeutics patents USP7 inhibitors

April 21, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...